製品名:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

IUPAC Name:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

CAS番号:1059735-34-0
分子式:C14H13Cl2N3
純度:97%
カタログ番号:CM105615
分子量:294.18

包装単位 有効在庫 価格(USD) 数量
CM105615-25g in stock Ōƚǟ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1059735-34-0
分子式:C14H13Cl2N3
融点:-
SMILESコード:ClC1=C2C(CN(CC3=CC=CC=C3)CC2)=NC(Cl)=N1
密度:
カタログ番号:CM105615
分子量:294.18
沸点:
MDL番号:MFCD11846183
保管方法:Cool,ventilated,dry

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products